Bellicum Pharmaceuticals (NASDAQ:BLCM – Get Rating) and Revance Therapeutics (NASDAQ:RVNC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
Risk and Volatility
Bellicum Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
This table compares Bellicum Pharmaceuticals and Revance Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Bellicum Pharmaceuticals and Revance Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Bellicum Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. Revance Therapeutics has a consensus price target of $23.60, suggesting a potential upside of 81.68%. Given Bellicum Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Bellicum Pharmaceuticals is more favorable than Revance Therapeutics.
Insider and Institutional Ownership
28.1% of Bellicum Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.9% of Revance Therapeutics shares are owned by institutional investors. 2.7% of Bellicum Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Revance Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Bellicum Pharmaceuticals and Revance Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bellicum Pharmaceuticals||$6.20 million||1.60||-$9.70 million||($0.29)||-3.97|
|Revance Therapeutics||$77.80 million||12.15||-$281.31 million||($4.04)||-3.22|
Bellicum Pharmaceuticals has higher earnings, but lower revenue than Revance Therapeutics. Bellicum Pharmaceuticals is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
Bellicum Pharmaceuticals beats Revance Therapeutics on 7 of the 13 factors compared between the two stocks.
About Bellicum Pharmaceuticals (Get Rating)
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
About Revance Therapeutics (Get Rating)
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.